Journey Medical Corp (DERM) reports robust revenue from Arosi launch, but faces challenges with Accutane sales and increased SG&A expenses.

ParkerVision (OTC:PRKR) reported no revenue (GAAP) for Q2 2025 and The company reported a net loss of $1.6 million for the second quarter of 2025, compared to a net loss of $0.3 million for the same ...